Kyverna Therapeutics, Inc. Common Stock (KYTX NASDAQ) stock market data APIs
$9.3351
0(0%)
as of May 8, 2026
Try our APIs with
free plan!
Kyverna Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Prev. Close
9.3351
Open
9.335
High
9.3747
Low
9.0804
52 wk Range
2.06-13.67
Market Cap
566 M
Shares Outstanding
60 530 K
EPS
-0.8
Beta
2.058
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kyverna Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kyverna Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Kyverna Therapeutics, Inc. Common Stock Fundamental Data
Kyverna Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -168 028 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kyverna Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-27
- EPS/Forecast: -0.8584
Get Kyverna Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kyverna Therapeutics, Inc. Common Stock News
New
Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic ar...
Kyverna's Jumps On Positive Primary Results From KYSA-8 Trial Of KYV-101 In Stiff Person Syndrome
(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), a late-stage clinical biopharmaceutical company, announced positive primary analysis results from its registrational Phase 2 trial, KYSA-8, of miv-cel or...
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS...
Kyverna rises on new mid-stage trial data for myasthenia gravis therapy
[Myasthenia gravis is shown using the text] Andrii Dodonov Shares of Kyverna Therapeutics (KYTX [https://seekingalpha.com/symbol/KYTX]) rose on Monday after the company announced long-term follow-up ...
Get Kyverna Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
